Drug Design Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
BCRX | B | BioCryst Pharmaceuticals, Inc. | -2.14 | |
XTLB | D | XTL Biopharmaceuticals Ltd. | 1.32 | |
SKYE | D | Skye Bioscience, Inc. | 0.00 | |
CYTK | D | Cytokinetics, Incorporated | -0.80 | |
PLRX | F | Pliant Therapeutics, Inc. | -0.19 | |
BIVI | F | BioVie Inc. | 2.77 |
Related Industries: Biotechnology
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
GERM | D | ETFMG Treatments Testing and Advancements ETF | 2.97 | |
XBI | C | SPDR S&P Biotech ETF | 2.4 | |
BBC | D | Virtus LifeSci Biotech Clinical Trials ETF | 1.72 | |
BTEC | C | Principal Healthcare Innovators Index ETF | 1.64 | |
BBP | C | BioShares Biotechnology Products Fund | 1.56 |
Compare ETFs
- Drug Design
Drug design, often referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense, drug design involves the design of molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it. Drug design frequently but not necessarily relies on computer modeling techniques. This type of modeling is sometimes referred to as computer-aided drug design. Finally, drug design that relies on the knowledge of the three-dimensional structure of the biomolecular target is known as structure-based drug design. In addition to small molecules, biopharmaceuticals including peptides and especially therapeutic antibodies are an increasingly important class of drugs and computational methods for improving the affinity, selectivity, and stability of these protein-based therapeutics have also been developed.The phrase "drug design" is to some extent a misnomer. A more accurate term is ligand design (i.e., design of a molecule that will bind tightly to its target). Although design techniques for prediction of binding affinity are reasonably successful, there are many other properties, such as bioavailability, metabolic half-life, side effects, etc., that first must be optimized before a ligand can become a safe and efficacious drug. These other characteristics are often difficult to predict with rational design techniques. Nevertheless, due to high attrition rates, especially during clinical phases of drug development, more attention is being focused early in the drug design process on selecting candidate drugs whose physicochemical properties are predicted to result in fewer complications during development and hence more likely to lead to an approved, marketed drug. Furthermore, in vitro experiments complemented with computation methods are increasingly used in early drug discovery to select compounds with more favorable ADME (absorption, distribution, metabolism, and excretion) and toxicological profiles.
Recent Comments
- TraderMike on Bollinger Band Squeeze
- TraderMike on Bollinger Band Squeeze
- OpenCat584 on Bollinger Band Squeeze
- Dr_Duru on Expansion Breakout
- TraderMike on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
From the Blog
Featured Articles